Replimune 10-Q: Going Concern Lifted After $141M Raise and FDA Approval

summarizeSummary

Replimune's 10-Q shows the going concern doubt is resolved after a $141M raise and FDA approval of TUDRIQEV, with cash runway beyond 12 months.

check_boxKey Events · Earnings and Guidance · REPL

• Going Concern Lifted

  The 10-Q states the conditions that raised substantial doubt about the company's ability to continue as a going concern have been alleviated by the $141.0 million net proceeds from the August 2026 equity offering.

• Cash Runway Extended

  Cash and short-term investments of $195.3 million as of June 30, 2026, plus the $141 million raise, fund operations for greater than twelve months, including the TUDRIQEV commercial launch.

• FDA Approval and Launch

  FDA granted accelerated approval for TUDRIQEV on August 6, 2026 for advanced melanoma; commercial launch is in progress.

• Equity Offering Completed

  On August 10, 2026, the company sold 9,701,490 shares at $12.06 and 2,736,340 pre-funded warrants at $12.0599, raising $141.0 million net.

auto_awesomeAnalysis · REPL · Life Sciences

Replimune's fiscal Q1 2027 10-Q confirms the going concern warning from the prior 10-K has been alleviated. The company raised $141 million net in an August 2026 equity offering and received FDA accelerated approval for TUDRIQEV, its first commercial product. Cash runway now extends beyond twelve months, funding the commercial launch. The quarterly net loss narrowed to $69.8 million from $86.7 million a year earlier, reflecting the 55% workforce reduction. The filing also discloses the SEC closed its investigation without recommending enforcement, while a new securities class action was filed on August 6, 2026.